Demographic and clinical characteristics of the cohort, overall and stratified by ever having HHV-6 reactivation or a delirium episode during the 12 weeks after HCT
| Characteristic . | Overall, no. (%) (N = 315) . | HHV-6 reactivation, no. (%) (n = 315) . | Delirium episode, no. (%) (n = 293)* . | ||
|---|---|---|---|---|---|
| No (n = 204) . | Yes (n = 111) . | No (n = 234) . | Yes (n = 59) . | ||
| Age, y | |||||
| ≤ 20 | 63 (20) | 33 (16) | 30 (27) | 34 (15) | 8 (14) |
| 21-30 | 22 (7) | 12 (6) | 10 (9) | 20 (9) | 2 (3) |
| 31-40 | 31 (10) | 22 (11) | 9 (8) | 20 (9) | 11 (19) |
| 41-50 | 51 (16) | 34 (17) | 17 (15) | 40 (17) | 11 (19) |
| > 50 | 148 (47) | 103 (51) | 45 (41) | 120 (51) | 27 (46) |
| Female sex | 126 (40) | 82 (40) | 44 (40) | 88 (38) | 31 (53) |
| Race/ethnicity | |||||
| White | 257 (82) | 171 (84) | 84 (76) | 195 (83) | 48 (81) |
| Hispanic | 10 (3) | 6 (3) | 4 (4) | 10 (4) | 1 (2) |
| Native American | 6 (2) | 3 (2) | 3 (3) | 3 (2) | 1 (2) |
| Other | 42 (13) | 23 (11) | 19 (17) | 26 (11) | 9 (15) |
| CMV serostatus | |||||
| Donor+/recipient+ | 80 (25) | 48 (24) | 32 (29) | 60 (26) | 14 (24) |
| Donor+/recipient− | 31 (10) | 21 (10) | 10 (9) | 21 (9) | 6 (10) |
| Donor−/recipient+ | 92 (29) | 57 (28) | 35 (31) | 66 (28) | 20 (34) |
| Donor−/recipient− | 112 (36) | 78 (38) | 34 (31) | 87 (37) | 19 (32) |
| Positive HSV serostatus | 265 (85) | 167 (83) | 98 (88) | 196 (84) | 52 (90) |
| Medical comorbidity | |||||
| Low | 93 (30) | 52 (26) | 41 (37) | 66 (28) | 11 (19) |
| Moderate | 95 (30) | 68 (33) | 27 (24) | 75 (32) | 14 (24) |
| High | 127 (40) | 84 (41) | 43 (39) | 93 (40) | 34 (57) |
| More advanced underlying disease | 174 (55) | 109 (53) | 65 (59) | 123 (53) | 35 (59) |
| Intrathecal methotrexate | 46 (15) | 26 (13) | 20 (18) | 29 (12) | 10 (17) |
| Total body irradiation | 199 (63) | 117 (57) | 82 (74) | 148 (63) | 34 (58) |
| Conditioning regimen | |||||
| Myeloablative | 169 (54) | 110 (54) | 59 (53) | 110 (47) | 43 (73) |
| Nonmyeloablative | 112 (35) | 79 (39) | 33 (30) | 96 (41) | 11 (19) |
| Reduced intensity | 34 (11) | 15 (7) | 19 (17) | 28 (12) | 5 (8) |
| HLA match | |||||
| Matched | 97 (31) | 73 (36) | 24 (22) | 70 (30) | 22 (37) |
| Mismatch | 11 (3) | 5 (2) | 6 (5) | 8 (3) | 1 (2) |
| Unrelated | 207 (66) | 126 (62) | 81 (73) | 156 (67) | 36 (61) |
| Cell source | |||||
| Bone marrow | 61 (19) | 34 (17) | 27 (24) | 39 (17) | 9 (15) |
| Cord | 21 (7) | 6 (3) | 15 (14) | 11 (5) | 5 (9) |
| Peripheral blood stem cell | 233 (74) | 164 (80) | 69 (62) | 184 (78) | 45 (76) |
| Characteristic . | Overall, no. (%) (N = 315) . | HHV-6 reactivation, no. (%) (n = 315) . | Delirium episode, no. (%) (n = 293)* . | ||
|---|---|---|---|---|---|
| No (n = 204) . | Yes (n = 111) . | No (n = 234) . | Yes (n = 59) . | ||
| Age, y | |||||
| ≤ 20 | 63 (20) | 33 (16) | 30 (27) | 34 (15) | 8 (14) |
| 21-30 | 22 (7) | 12 (6) | 10 (9) | 20 (9) | 2 (3) |
| 31-40 | 31 (10) | 22 (11) | 9 (8) | 20 (9) | 11 (19) |
| 41-50 | 51 (16) | 34 (17) | 17 (15) | 40 (17) | 11 (19) |
| > 50 | 148 (47) | 103 (51) | 45 (41) | 120 (51) | 27 (46) |
| Female sex | 126 (40) | 82 (40) | 44 (40) | 88 (38) | 31 (53) |
| Race/ethnicity | |||||
| White | 257 (82) | 171 (84) | 84 (76) | 195 (83) | 48 (81) |
| Hispanic | 10 (3) | 6 (3) | 4 (4) | 10 (4) | 1 (2) |
| Native American | 6 (2) | 3 (2) | 3 (3) | 3 (2) | 1 (2) |
| Other | 42 (13) | 23 (11) | 19 (17) | 26 (11) | 9 (15) |
| CMV serostatus | |||||
| Donor+/recipient+ | 80 (25) | 48 (24) | 32 (29) | 60 (26) | 14 (24) |
| Donor+/recipient− | 31 (10) | 21 (10) | 10 (9) | 21 (9) | 6 (10) |
| Donor−/recipient+ | 92 (29) | 57 (28) | 35 (31) | 66 (28) | 20 (34) |
| Donor−/recipient− | 112 (36) | 78 (38) | 34 (31) | 87 (37) | 19 (32) |
| Positive HSV serostatus | 265 (85) | 167 (83) | 98 (88) | 196 (84) | 52 (90) |
| Medical comorbidity | |||||
| Low | 93 (30) | 52 (26) | 41 (37) | 66 (28) | 11 (19) |
| Moderate | 95 (30) | 68 (33) | 27 (24) | 75 (32) | 14 (24) |
| High | 127 (40) | 84 (41) | 43 (39) | 93 (40) | 34 (57) |
| More advanced underlying disease | 174 (55) | 109 (53) | 65 (59) | 123 (53) | 35 (59) |
| Intrathecal methotrexate | 46 (15) | 26 (13) | 20 (18) | 29 (12) | 10 (17) |
| Total body irradiation | 199 (63) | 117 (57) | 82 (74) | 148 (63) | 34 (58) |
| Conditioning regimen | |||||
| Myeloablative | 169 (54) | 110 (54) | 59 (53) | 110 (47) | 43 (73) |
| Nonmyeloablative | 112 (35) | 79 (39) | 33 (30) | 96 (41) | 11 (19) |
| Reduced intensity | 34 (11) | 15 (7) | 19 (17) | 28 (12) | 5 (8) |
| HLA match | |||||
| Matched | 97 (31) | 73 (36) | 24 (22) | 70 (30) | 22 (37) |
| Mismatch | 11 (3) | 5 (2) | 6 (5) | 8 (3) | 1 (2) |
| Unrelated | 207 (66) | 126 (62) | 81 (73) | 156 (67) | 36 (61) |
| Cell source | |||||
| Bone marrow | 61 (19) | 34 (17) | 27 (24) | 39 (17) | 9 (15) |
| Cord | 21 (7) | 6 (3) | 15 (14) | 11 (5) | 5 (9) |
| Peripheral blood stem cell | 233 (74) | 164 (80) | 69 (62) | 184 (78) | 45 (76) |
CMV indicates cytomegalovirus; HSV, herpes simplex virus; and HLA, human leukocyte antigen.
A total of 22 patients were too young or not developmentally able to participate in delirium assessments.